

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



24 July 2025

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of settlement agreement in the In re Generic Pharmaceuticals Pricing Antitrust Litigation

This is to inform that Sun Pharmaceutical Industries Limited (“Sun Pharma”) subsidiaries, Sun Pharmaceutical Industries, Inc. (“SPII”) and Taro Pharmaceuticals U.S.A., Inc. (“Taro”), have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, U.S.

Under the terms of the settlement agreement, the subsidiaries will make an aggregate payment of US\$ 200 Million in exchange for a full release of all claims asserted against them (and all of their current and former parents, affiliates, predecessors and successors as well as their current and former directors, officers, employees and representatives) in the End Purchaser Action by the settlement class members. The settlement amounts may be reduced if more than a certain percentage of the total insured class members opt out of the putative class.

The settlement agreement is entered into without admission of any wrongdoing in the End Purchaser Action. The settlement agreement is subject to court approval.

For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983